# Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract Surgery

> **NCT06164743** · PHASE2 · COMPLETED · sponsor: **VivaVision Biotech, Inc** · enrollment: 91 (actual)

## Conditions studied

- Inflammation

## Interventions

- **DRUG:** VVN461 Ophthalmic Solution 1.0%
- **DRUG:** VVN461 Ophthalmic Solution 0.5%
- **DRUG:** Vehicle

## Key facts

- **NCT ID:** NCT06164743
- **Lead sponsor:** VivaVision Biotech, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-11
- **Primary completion:** 2024-05-15
- **Final completion:** 2024-05-15
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2025-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06164743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06164743, "Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract Surgery". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06164743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*